Circle's Arc blockchain reached over $1 billion in USDC supply just six weeks after its public mainnet launch in mid-September 2026, marking a 109% growth in 30 days. This milestone is notable as it occurred while the global stablecoin market was contracting, highlighting strong adoption on Arc. However, about 73% of the USDC supply is concentrated in the top four addresses, which may affect the supply's stability and distribution. Going forward, key points to watch include whether growth sustains, if address concentration decreases, and if other stablecoins join the network.
The USDC supply on Circle's Arc blockchain recently surpassed $1 billion after a 109.4% increase in 30 days, providing context for readers. For those tracking major cryptocurrencies on Pluang as of Nov 02, 2026 19:42 WIB, 7 out of 50 assets rose while 42 fell. Notable movers include EOS at Rp12,649 with an 8.13% gain and a typical hold time of 87 days, BAT at Rp2,394 down 5.58% with 73% sell order activity, and CRV at Rp4,969 down 4.46% with 57% sell order activity and a 62-day hold time.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Tigo Energy, Fluence Energy, and Anavex Life Sciences. The lawsuits allege these companies made false or misleading stat...
Heineken N.V. has repurchased a total of 9,510,681 shares under the second tranche of its €1.5 billion share buyback program, spending €679.2 million as of October 30, 2026. The company bought 159,700 shares on the exchange and 160,530 shares from He...
Alvotech, a global biotech company specializing in biosimilars, announced its management team will participate in several investor conferences in November 2026, including events in London, Oslo, and Stockholm. These presentations and fireside chats w...
Alvotech, a global biotech company specializing in biosimilar medicines, announced its management team will participate in several investor conferences throughout November 2026. These include events in London, Oslo, and Stockholm, featuring presentat...
Alvotech, a global biotechnology company specializing in biosimilar medicines, will participate in four international investor conferences in November held in the UK, Norway, and Sweden. These events include presentations and analyst discussions host...
